



RECEIVED

APR 20 2000

TECH CENTER 1600/2900 Sheet 1 of 3

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DKT. NO.

BAYER 11 C1

SERIAL NO.

09/458,014

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Jacques DUMAS, et al.

FILING DATE

December 10, 1999

GROUP

1614


U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
<i>R</i>	AA 3,823,161	07/09/74	Lesser			
<i>R</i>	AB 5,130,331	07/14/92	Pascual			
<i>R</i>	AC 4,740,520	04/26/88	Hallenbach et al.			
<i>R</i>	AD 4,808,588	02/28/89	King			
<i>R</i>	AE 3,828,001	08/06/74	Broad et al.			
<i>R</i>	AF 3,424,760	01/28/69	Helsley et al.			
<i>R</i>	AG 3,424,761	01/28/69	Helsley et al.			
<i>R</i>	AH 3,424,762	01/28/69	Helsley et al.			
<i>R</i>	AI 4,071,524	01/31/78	Banitt			
<i>R</i>	AJ 4,111,683	09/05/78	Singer			
<i>R</i>	AK 4,437,878	03/20/88	Acker et al.			
<i>R</i>	AL 4,643,849	02/17/87	Hirai et al.			
<i>R</i>	AM 5,773,459	06/30/98	Tang et al.			
<i>R</i>	AN 5,508,288	04/16/96	Forbes et al.			
<i>R</i>	AO 4,062,861	12/13/77	Yukinaga et al.			
<i>R</i>	AP 4,111,680	09/05/78	Yukinaga et al.			
<i>R</i>	AQ 4,116,671	09/26/78	Yukinaga et al.			
<i>R</i>	AR 4,212,981	07/15/80	Yukinaga et al.			
<i>R</i>	AS 5,162,360	11/10/92	Creswell et al.			
<i>R</i>	AT 5,059,614	10/22/91	Lepage et al.			
<i>R</i>	AU 4,514,571	04/30/85	Nakai et al.			
<i>R</i>	AV 3,754,887	08/28/73	Brantley			
<i>R</i>	AW 3,743,498	07/03/73	Brantley			
<i>R</i>	AX 3,547,940	12/15/70	Brantley			
<i>R</i>	AY 3,646,059	02/29/72	Brantley			
<i>R</i>	AZ 5,319,099	06/07/94	Kamata et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
<i>R</i>	BA EP 335156	03/11/89	European				X
<i>R</i>	BB EP 459887	05/28/91	European				X
<i>R</i>	BC EP 371876	11/28/89	European				X
<i>R</i>	BD 93/24458	12/9/93	WO			X	
<i>R</i>	BE 2,146,707	10/12/95	Canada			X	

J. C. Jones 3/4/02



09/458,014

<i>R</i>	BF	96/40673	12/19/96	WO		X	
<i>R</i>	BG	94/14801	07/07/94	WO		X	
<i>R</i>	BH	94/25012	11/10/94	WO		X	
<i>R</i>	BI	1,590,870	06/10/81	England		X	
<i>R</i>	BJ	93/18028	09/16/93	WO		X	
<i>R</i>	BK	94/18170	08/18/94	WO		X	
<i>R</i>	BL	DE 3305866 A1	02/19/83	Germany			X
<i>R</i>	BM	95/02591	01/26/95	WO		X	
<i>R</i>	BN	95/13067	05/18/95	WO		X	
<i>R</i>	BO	95/07922	03/23/95	WO		X	
<i>R</i>	BP	95/31451	11/23/95	WO		X	
<i>R</i>	BQ	A1 96/40675	12/19/96	WO		X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	BR	Dumas, J., "CAS Substructure," May 6, 1997, pages 1-29.
	BS	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pages 1-19.
	BT	Scott, Bill, "Substructure #1," November 25, 1997, pages 1-19.
	BU	Scott, Bill, "Substructure #2," November 25, 1997, pages 1-3.
	BV	Scott, Bill, "Selected compounds," November 25, 1997, pages 1-32.
	BW	"Beilstein number" Collection, 28 pages. <i>NO DATE</i>
	BX	"Beilstein Collection," 4 pages. <i>NO DATE</i>
	BY	Scott, Bill, "Markush Patent Search," December 2, 1997, pages 1-28.
	BZ	Scott, Bill, "Substructure Search," December 2, 1997, pages 1-51.
	CA	Substructure Search, pages 1-30.
	CB	Derwent World Patents Index Search, pages 20-26.
	CC	Abstract of EP 116,932
	CD	Abstract of EP 676,395
	CE	Abstract of EP 202,538
	CF	Abstract of EP 16,371
<i>R</i>	CG	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
<i>R</i>	CH	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.
<i>R</i>	CI	Audia, James E., et al., "Potent, Selective Tetrahydro- β -carboline Antagonists of the Serotonin 2B (5HT _{2B}) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
<i>R</i>	CJ	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT _{2B} Receptor Antagonist," March 17, 1995, pages 855-57.
<i>R</i>	CK	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. ¹ A Generalised Monocyclic Rearrangement," 1967, 2005-07.
<i>R</i>	CL	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
<i>R</i>	CM	G. Daum, et al., "The ins and outs of Raf Kinases," TIBS 19, November 1994, pages 474-80.
<i>R</i>	CN	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
<i>R</i>	CO	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
<i>R</i>	CP	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.

TJ Cuana 3/4/02

09/458,014

RJT(lvb)K:\PAT\Bayer\11\c\1449-3.wpd